Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900302 · ClinicalTrials.gov registry record
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
A clinical trial, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 98
- Enrollment target
NCT00900302 is a clinical trial that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 98 participants.
The verdict
NCT00900302 has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is evaluating OX-40 protein expression in the sentinel lymph nodes of patients with cancer.
Interventions
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00900302
The ClinicalTrials.gov registry entry for NCT00900302 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which protein expression analysis is the first listed.
NCT00900302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00900302 about?
NCT00900302 is a clinical study titled "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer". RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is evaluating OX-40 protei...
What is the current status of trial NCT00900302?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2005-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00900302?
The interventions under investigation include: protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER).
Who is sponsoring clinical trial NCT00900302?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.